

Updated: 05/19/2026

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition		Active Research Studies	St. Luke's Contact
<u>ANATOMICAL SITE</u>	<u>RESEARCH BASE &amp; REFERENCE #</u>	<u>STUDY TITLE</u>	<u>ST. LUKE'S CONTACT</u>
<u>SMOKING CESSATION</u>	A211901 NCT05008848	<a href="#">Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions</a>	Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>MULTICANCER EARLY DETECTION</u>	Alliance A212102 NCT05334069	<a href="#">Blinded Reference Set for Multicancer Early Detection Blood Tests</a>	Frances V. 218-249-5005 Cade M. 218-249-5647 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>BREAST GASTRIC/ABDOMINAL THORACIC</u>	iCaRe <sup>2</sup>	<a href="#">Integrated Cancer Repository for Cancer Research</a>	Frances V. 218-249-5005 Cade M. 218-249-5647 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>Breast Triple Negative</u>	Alliance A012103 NCT05812807	<a href="#">Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab</a>	Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>Breast HR+ HER2-</u>	SWOG S2206 NCT0605837	<a href="#">Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer</a>	Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>PROSTATE</u>	NRG-GU013 NCT05946213	<a href="#">Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer</a>	Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>PANCREAS</u>	EA2192 NCT04858334	<a href="#">APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation</a>	Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>NSCLC</u>	ARTEMIDE Lung-02 NCT06692738	<a href="#">A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1</a>	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 <a href="#">ASL-Whiteside@aspirus.org</a>

<u>NSCLC</u>	HARMONi7 NCT6767514	<a href="#">Summit HARMONi 7: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression</a>	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>NSCLC</u>	Andrometa NCT07155187	<a href="#">Andrometa: Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI</a>	Ahnna P. RN, 218-249-5581 Charity G. RN, 218-249-5177 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>Hereditary Hemochromatosis</u>	Ferroclear NCT07332091	<a href="#">A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis</a>	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>Pan Cancer</u>	Caris Biorepository NCT1499394	<a href="#">The Caris Biorepository Research Protocol</a>	Ahnna P. RN, 218-249-5581 Charity G. RN, 218-249-5177 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>LEUKEMIA</u>	ReVenG NCT04895436	<a href="#">Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)</a>	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>SOLID TUMORS WITH BRAF ALTERATIONS</u>	FORE8394 NCT02428712	<a href="#">A phase 2 trial to assess the efficacy and safety of plixorafenib, an inhibitor of BRAF class I and II alterations, in patients with BRAF alterations</a>	Charity G. RN, 218-249-5177 Ahnna P. RN, 218-249-5581 <a href="#">ASL-Whiteside@aspirus.org</a>
<u>Breast, Colorectal, Melanoma, non-Hodgkin Lymphoma, NSCLC</u>	Wake Forest, Alliance WF2304- A172401 NCT06418204	<a href="#">Assessing Benefits and Harms of Cannabis/ Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics (COSMIC)</a>	Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="#">ASL-Whiteside@aspirus.org</a>

<p><u>Various</u></p>	<p>EAY191 NCT05564377</p>	<p>Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial</p>	<p>Cade M. 218-249-5647 Frances V. 218-249-5005 <a href="mailto:ASL-Whiteside@aspirus.org">ASL-Whiteside@aspirus.org</a></p>
-----------------------	-------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------